WO2026068729A1 - Anti-mir-27b pour le traitement de la maladie de parkinson - Google Patents

Anti-mir-27b pour le traitement de la maladie de parkinson

Info

Publication number
WO2026068729A1
WO2026068729A1 PCT/EP2025/077662 EP2025077662W WO2026068729A1 WO 2026068729 A1 WO2026068729 A1 WO 2026068729A1 EP 2025077662 W EP2025077662 W EP 2025077662W WO 2026068729 A1 WO2026068729 A1 WO 2026068729A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
lna
seq
disease
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/077662
Other languages
English (en)
Inventor
Lluis RIVERA PONSATI
Janine TERRA ERLER
Henrik Klitgaard
Sakari Kauppinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neumirna Therapeutics ApS
Original Assignee
Neumirna Therapeutics ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neumirna Therapeutics ApS filed Critical Neumirna Therapeutics ApS
Publication of WO2026068729A1 publication Critical patent/WO2026068729A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de composés anti-miR-27b pour le traitement ou le soulagement de la maladie de Parkinson. On s'est aperçu que les composés de l'invention sont aptes à prévenir la dégradation neuronale dopaminergique dans des modèles de maladie de Parkinson, ainsi qu'à agir sur des voies importantes associées au développement de la maladie de Parkinson.
PCT/EP2025/077662 2024-09-26 2025-09-26 Anti-mir-27b pour le traitement de la maladie de parkinson Pending WO2026068729A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA202400887 2024-09-26
DKPA202400887 2024-09-26

Publications (1)

Publication Number Publication Date
WO2026068729A1 true WO2026068729A1 (fr) 2026-04-02

Family

ID=97299958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/077662 Pending WO2026068729A1 (fr) 2024-09-26 2025-09-26 Anti-mir-27b pour le traitement de la maladie de parkinson

Country Status (1)

Country Link
WO (1) WO2026068729A1 (fr)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000056748A1 (fr) 1999-03-18 2000-09-28 Exiqon A/S Analogues de xylo-lna
WO2000056746A2 (fr) 1999-03-24 2000-09-28 Exiqon A/S Synthese perfectionnee de [2.2.1]bicyclo-nucleosides
WO2001025248A2 (fr) 1999-10-04 2001-04-12 Exiqon A/S Conception d'un oligonucleotide de recrutement de rnase h a haute affinite
WO2002028875A2 (fr) 2000-10-04 2002-04-11 Cureon A/S Synthese perfectionnee d'analogues d'acides nucleiques bloques de purine
WO2003006475A2 (fr) 2001-07-12 2003-01-23 Santaris Pharma A/S Elaboration de phosphoramidites d'acide nucleique verrouille
WO2003095467A1 (fr) 2002-05-08 2003-11-20 Santaris Pharma A/S Synthèse de dérivés d'acides nucléiques lna
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
WO2013036868A1 (fr) 2011-09-07 2013-03-14 Marina Biotech Inc. Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
WO2014201301A1 (fr) * 2013-06-12 2014-12-18 New York University Oligonucléotides anti-mir-27b et anti-mir-148a à utiliser en tant qu'outils thérapeutiques pour le traitement de dyslipidémies et de maladies cardiovasculaires
WO2015071388A1 (fr) 2013-11-14 2015-05-21 Roche Innovation Center Copenhagen A/S Composés conjugués antisens apob
US20240182889A1 (en) * 2021-03-26 2024-06-06 Neumirna Therapeutics Aps Microrna-27b inhibitors
US20240240188A1 (en) * 2021-06-04 2024-07-18 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014226A2 (fr) 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000056748A1 (fr) 1999-03-18 2000-09-28 Exiqon A/S Analogues de xylo-lna
WO2000056746A2 (fr) 1999-03-24 2000-09-28 Exiqon A/S Synthese perfectionnee de [2.2.1]bicyclo-nucleosides
WO2001025248A2 (fr) 1999-10-04 2001-04-12 Exiqon A/S Conception d'un oligonucleotide de recrutement de rnase h a haute affinite
WO2002028875A2 (fr) 2000-10-04 2002-04-11 Cureon A/S Synthese perfectionnee d'analogues d'acides nucleiques bloques de purine
WO2003006475A2 (fr) 2001-07-12 2003-01-23 Santaris Pharma A/S Elaboration de phosphoramidites d'acide nucleique verrouille
WO2003095467A1 (fr) 2002-05-08 2003-11-20 Santaris Pharma A/S Synthèse de dérivés d'acides nucléiques lna
WO2007031091A2 (fr) 2005-09-15 2007-03-22 Santaris Pharma A/S Composes antagonistes d'arn de modulation de l'expression de p21 ras
WO2013036868A1 (fr) 2011-09-07 2013-03-14 Marina Biotech Inc. Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
WO2014201301A1 (fr) * 2013-06-12 2014-12-18 New York University Oligonucléotides anti-mir-27b et anti-mir-148a à utiliser en tant qu'outils thérapeutiques pour le traitement de dyslipidémies et de maladies cardiovasculaires
WO2015071388A1 (fr) 2013-11-14 2015-05-21 Roche Innovation Center Copenhagen A/S Composés conjugués antisens apob
US20240182889A1 (en) * 2021-03-26 2024-06-06 Neumirna Therapeutics Aps Microrna-27b inhibitors
US20240240188A1 (en) * 2021-06-04 2024-07-18 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
BARISCIANO GCOLANGELO TROSATO VMUCCILLO LTADDEI MLIPPOLITO LCHIARUGI PGALGANI MBRUZZANITI SMATARESE G: "miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer", BRITISH JOURNAL OF CANCER 2020, vol. 122, no. 9 122, 2020, pages 1354 - 1366, XP037524650, Retrieved from the Internet <URL:https://doi.org/10.1038/s41416-020-0773-2> DOI: 10.1038/s41416-020-0773-2
CARDO LFCOTO ERIBACOBA RMENÉNDEZ MMORIS GSUAREZ EALVAREZ V: "MiRNA profile in the substantia nigra of Parkinson's disease and healthy subjects", J MOL NEUROSCI, vol. 54, 2014, pages 830 - 836, XP035409148, Retrieved from the Internet <URL:https://doi.org/10.1007/S12031-014-0428-Y> DOI: 10.1007/s12031-014-0428-y
CELL, vol. 126, no. 4, 10 August 2006 (2006-08-10), pages 663 - 76
CEN XCHEN YXU XWU RHE FZHAO QSUN QYI CWU JNAJAFOV A: "Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer's disease mouse model", NAT COMMUN, 2020, pages 11, Retrieved from the Internet <URL:https://doi.org/10.1038/S41467-020-19547-6>
CHEN LYANG JLÜ JCAO SZHAO QYU Z: "Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples", BRAIN BEHAV, vol. 8, 2018, pages 00941, Retrieved from the Internet <URL:https://doi.org/10.1002/BRB3.941>
CLARK EHDE LA TORRE AVHOSHIKAWA TBRISTON T: "Targeting mitophagy in Parkinson's disease", J BIOL CHEM, 2021, pages 296, Retrieved from the Internet <URL:https://doi.org/10.1074/JBC.REV120.014294>
FAZELI SMOTOVALI-BASHI MPEYMANI MHASHEMI MSETEMADIFAR MNASR-ESFAHANI MHGHAEDI K: "A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson's patients is associated with the early stage onset of disease", PLOS ONE, vol. 15, 2020, pages 0240855, Retrieved from the Internet <URL:https://doi.org/10.1371/JOURNAL.PONE.0240855>
FIVENSON EMLAUTRUP SSUN NSCHEIBYE-KNUDSEN MSTEVNSNER TNILSEN HBOHRVAFANG EF: "Mitophagy in neurodegeneration and aging", NEUROCHEM INT, vol. 109, 2017, pages 202 - 209, XP085239574, Retrieved from the Internet <URL:https://doi.org/10.1016/J.NEUINT.2017.02.007> DOI: 10.1016/j.neuint.2017.02.007
FLUITER ET AL., MOL. BIOSYST, vol. 10, 2009, pages 1039
FREIERALTMANN, NUCL. ACID. RES, vol. 25, 1997, pages 4429 - 4443
GUERAU-DE-ARELLANO MSMITH KMGODLEWSKI JLIU YWINGER RLAWLER SEWHITACRE CCRACKE MKLOVETT-RACKE AE: "Micro-RNA dysregulation in multiple sclerosis favours proinflammatory T-cell-mediated autoimmunity", BRAIN, vol. 134, 2011, pages 3575, Retrieved from the Internet <URL:https://doi.org/10.1093/BRAIN/AWR262>
HO MS: "Microglia in parkinson's disease", ADV EXP MED BIOL, vol. 1175, 2019, pages 335 - 353, Retrieved from the Internet <URL:https://doi.org/10.1007/978-981-13-9913-8_13/FIGURES/3>
KASTEN MHARTMANN CHAMPF JSCHAAKE SWESTENBERGER AVOLLSTEDT EJBALCK ADOMINGO AVULINOVIC FDULOVIC M: "Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review", MOV DISORD, vol. 33, 2018, pages 730 - 741, Retrieved from the Internet <URL:https://doi.org/10.1002/mds.27352>
KIM J, FIESEL FC, BELMONTE KC, HUDEC R, WANG WX, KIM C, NELSON PT, SPRINGER W, KIM J.: "miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1", MOL NEURODEGENER, vol. 11, 2016, pages 55, Retrieved from the Internet <URL:https://doi.org/10.1186/S13024-016-0121-4>
KIM JAEKWANG ET AL: "miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1)", MOLECULAR NEURODEGENERATION, vol. 11, no. 1, 26 July 2016 (2016-07-26), Lo, XP093360958, ISSN: 1750-1326, Retrieved from the Internet <URL:http://link.springer.com/content/pdf/10.1186/s13024-016-0121-4.pdf> DOI: 10.1186/s13024-016-0121-4 *
KIM JINOUE KISHII JVANTI WBVORONOV S VMURCHISON EHANNON GABELIOVICH A: "A microRNA feedback circuit in midbrain dopamine neurons", SCIENCE, vol. 317, no. 1979, 2007, pages 1220 - 1224, Retrieved from the Internet <URL:https://doi.org/10.1126/SCIENCE.1140481/SUPPL_FILE/KIM.SOM.PDF>
L WJ LY LY CW LH ZA Z, N L, MICRORNA CANDIDATE BIOMARKERS FOR PARKINSON'S DISEASE AND IDIOPATHIC REM SLEEP BEHAVIOR DISORDER, 2021, Retrieved from the Internet <URL:https://doi.org/10.21203/RS.3.RS-1163742N1>
LI LQI CLIU YSHEN YZHAO XQIN HZHANG YYU T: "MicroRNA miR-27b-3p regulate microglial inflammation response and cell apoptosis by inhibiting A20 (TNF-a-induced protein 3", BIOENGINEERED, vol. 12, 2021, pages 9902 - 9913, Retrieved from the Internet <URL:https://doi.org/10.1080/21655979.2021.1969195/SUPPL_FILE/KBIE_A_1969195_SM2028.ZIP>
MEREDITH GERADEMACHER DJ: "MPTP mouse models of Parkinson's disease: an update", J PARKINSONS DIS, vol. 1, 2011, pages 19 - 33, Retrieved from the Internet <URL:https://doi.org/10.3233/JPD-2011-11023>
MIRON VEPRILLER J: "Investigating Microglia in Health and Disease: Challenges and Opportunities", TRENDS IMMUNOL, vol. 41, 2020, pages 785 - 793, Retrieved from the Internet <URL:https://doi.org/10.1016/j.it.2020.07.002>
MURATA HTAKAMATSU HLIU SKATAOKA KHUH NHSAKAGUCHI M: "NRF2 Regulates PINK1 Expression under Oxidative Stress Conditions", PLOS ONE, vol. 10, 2015, pages 0142438, Retrieved from the Internet <URL:https://doi.org/10.1371/JOURNAL.PONE.0142438>
OLSSON ET AL., J NEUROSCI, vol. 15, 1995, pages 3863 - 75
PALLAN ET AL., CHEM COMMUN (CAMB)., vol. 48, no. 66, 25 August 2012 (2012-08-25), pages 8195 - 8197
PENG ET AL., J FLUOR CHEM, vol. 129, no. 9, September 2008 (2008-09-01), pages 743 - 766
POEWE W, SEPPI K, TANNER CM, HALLIDAY GM, BRUNDIN P, VOLKMANN J, SCHRAG AE, LANG AE: "Parkinson disease", NAT REV DIS PRIMERS, vol. 3, 2017, pages 17013, Retrieved from the Internet <URL:https://doi.org/10.1038/nrdp.2017.13>
PONSATI ET AL: "Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson's Disease - MDS Abstracts", JOURNAL OF MOLECULAR NEUROSCIENCE, 27 September 2024 (2024-09-27), US, pages 830 - 836, XP093360982, ISSN: 0895-8696, Retrieved from the Internet <URL:https://www.mdsabstracts.org/abstract/targeting-mir-27-with-antisense-oligonucleotides-for-disease-modification-in-parkinsons-disease/> DOI: 10.1007/s12031-014-0428-y *
RENNEBERG ET AL., NUCLEIC ACIDS RES., vol. 30, no. 13, 1 July 2002 (2002-07-01), pages 2751 - 2757
SIMOLA NMORELLI MCARTA AR: "The 6-hydroxydopamine model of Parkinson's disease", NEUROTOX RES, vol. 11, 2007, pages 151 - 167, Retrieved from the Internet <URL:https://doi.org/10.1007/BF03033565>
SINGH FPRESCOTT ARROSEWELL PBALL GREITH ADGANLEY IG: "Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice", ELIFE, 2021, pages 10, Retrieved from the Internet <URL:https://doi.org/10.7554/ELIFE.67604>
SNEAD ET AL., MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 2, 2013, pages 103
TANSEY MGWALLINGS RLHOUSER MCHERRICK MKKEATING CEJOERS V: "Inflammation and immune dysfunction in Parkinson disease", NAT REV IMMUNOL, 2022, Retrieved from the Internet <URL:https://doi.org/10.1038/s41577-022-00684-6>
UHLMANN, CURR. OPINION IN DRUG DEVELOPMENT, vol. 3, no. 2, 2000, pages 293 - 213
WANG XMICHAELIS EK: "Selective neuronal vulnerability to oxidative stress in the brain", FRONT AGING NEUROSCI, vol. 2, 2010, pages 12, Retrieved from the Internet <URL:https://doi.org/10.3389/fnagi.2010.00012>
XU W, LI F, LIU Z, XU Z, SUN B, CAO J, LIU Y, XU W, LI F, LIU Z, XU Z, SUN B, CAO J, LIU Y: "MicroRNA-27b inhibition promotes Nrf2/ARE pathway activation and alleviates intracerebral hemorrhage-induced brain injury", ONCOTARGET, vol. 8, 2017, pages 70669 - 70684, Retrieved from the Internet <URL:https://doi.org/10.18632/ONCOTARGET.19974>

Similar Documents

Publication Publication Date Title
Hoene et al. Interleukin-6 promotes myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway
Chu-Tan et al. MicroRNA-124 dysregulation is associated with retinal inflammation and photoreceptor death in the degenerating retina
Lou et al. miR-124 ameliorates depressive-like behavior by targeting STAT3 to regulate microglial activation
Lv et al. MicroRNA let-7c-5p improves neurological outcomes in a murine model of traumatic brain injury by suppressing neuroinflammation and regulating microglial activation
Mo et al. MicroRNA‐365 modulates astrocyte conversion into neuron in adult rat brain after stroke by targeting Pax6
Xiaoying et al. CircHivep2 contributes to microglia activation and inflammation via miR‐181a‐5p/SOCS2 signalling in mice with kainic acid‐induced epileptic seizures
US20180312839A1 (en) Methods and compositions for increasing smn expression
US12281310B2 (en) Use of trinucleotide repeat RNAs to treat cancer
Kolosowska et al. Intracerebral overexpression of miR-669c is protective in mouse ischemic stroke model by targeting MyD88 and inducing alternative microglial/macrophage activation
JP2021520200A (ja) 非神経細胞のニューロンへの再プログラミング、及び神経変性疾患または障害を治療するための方法と組成物
Hou et al. MiR-27b promotes muscle development by inhibiting MDFI expression
US20200032268A1 (en) TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS
Wang et al. miR‐30b Promotes spinal cord sensory function recovery via the Sema3A/NRP‐1/PlexinA1/RhoA/ROCK Pathway
CN115176002A (zh) 用于神经保护的方法和组合物
Yang et al. Sonic hedgehog released from scratch-injured astrocytes is a key signal necessary but not sufficient for the astrocyte de-differentiation
Meares et al. MicroRNA‐31 is required for astrocyte specification
AU2020296104A1 (en) PPM1A inhibitors and methods of using same
Weng et al. MicroRNA-451 aggravates kainic acid-induced seizure and neuronal apoptosis by targeting GDNF
Li et al. The role of biomechanical forces and MALAT1/miR‐329‐5p/PRIP signalling on glucocorticoid‐induced osteonecrosis of the femoral head
WO2026068729A1 (fr) Anti-mir-27b pour le traitement de la maladie de parkinson
Jiang et al. miR-24 protects against ischemia-induced brain damage in rats via regulating microglia polarization by targeting Clcn3
US11013753B2 (en) TLX and MIR-219 as potential therapeutic targets for neurodevelopmental disorders
EP3587575A1 (fr) Mirna mir-218 et son utilisation pour la stimulation des cellules souches mésenchymateuses
Wang et al. MicroRNAs as biomarkers in molecular diagnosis of refractory epilepsy
US20190055553A1 (en) Methods for identifying and targeting non-coding rna scaffolds